New BA.3.2 ‘Cicada’ Covid Variant Detected in the US
A new Covid-19 subvariant, BA.3.2, nicknamed the “Cicada” variant, has been detected in the United States and other countries. It comes from the Omicron family and has a high number of mutations, making it capable of partially avoiding immunity from previous infections or vaccines. However, experts say it does not currently cause more severe illness.
The BA.3.2 variant was first spotted in South Africa in late 2024 and has since spread to parts of Europe, Australia, and the US. The World Health Organization (WHO) has listed it as a “variant under monitoring,” meaning it is being watched closely, though it is not considered a major global threat yet.
BA.3.2 carries over 50 mutations in the spike protein compared to earlier BA.3 lineages and more than 70 compared to the original Wuhan virus. Scientists are monitoring it for three main reasons:
- Immune Evasion: It may partly escape protection from prior infection or vaccination.
- High Mutations: Its unusual mutation profile could affect how it spreads or reacts to antibodies.
- Global Spread: Detected in multiple countries, including growth signals in wastewater studies.
Symptoms linked to BA.3.2 are mostly mild and similar to other Omicron variants. These include cough, fatigue, runny nose, headache, sore throat, mild fever, and body aches. Rarely, some people may experience loss of taste or smell, night sweats, or skin rashes.
Currently, there is no evidence of higher hospitalisation or death rates. Vaccines are still expected to protect against severe disease, even if infections occur.
Health experts advise staying updated with boosters, following precautions in crowded areas, testing if symptomatic, and protecting vulnerable people. BA.3.2 reminds the world that Covid-19 continues to evolve, and vigilance remains crucial.
